Secondary head and neck cancer in patients with history of hematological malignancy

Head & Neck
Joseph Chun-Kit ChungWilliam Ignace Wei

Abstract

Head and neck cancer is a common second cancer in patients with a history of hematological malignancies. The purpose of this study was present the clinical characteristics and treatment outcomes of this group of patients. A retrospective analysis was conducted of all patients who had a history of hematological malignancy and developed head and neck cancer in a 10-year period. The cohort had 10 patients; median age was 45.8 years. Most patients were nonsmokers and nondrinkers. Seven patients had chronic graft-versus-host disease. The median interval between the completion of treatment of hematological malignancy and the development of head and neck cancers was 8.79 years (range, 2.33-26.83 years). Six patients were alive and disease-free, 3 developed local recurrence, and 3 had metachronous head and neck cancers. The risk factors and etiology of head and neck cancers in patients with hematological malignancy may be different from the ordinary population.

References

Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R LowskyH Messner
Jan 1, 1993·Journal of Clinical Microbiology·Y S TyanY S Chang
Mar 27, 1997·The New England Journal of Medicine·R E CurtisJ D Boice
May 16, 2000·Bone Marrow Transplantation·G Favre-SchmuzigerA Gratwohl
Jun 22, 2000·International Journal of Cancer. Journal International Du Cancer·C C WangJ H Hong
Mar 21, 2002·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·L ZhangM P Rosin
Dec 20, 2002·Nature·Lisa M Coussens, Zena Werb
Oct 22, 2003·Archives of Otolaryngology--head & Neck Surgery·Elizabeth A SiskErle Robertson
Jun 18, 2004·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Boudewijn J M BraakhuisRuud H Brakenhoff
Sep 29, 2004·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·R M HermannH Schmidberger
Aug 9, 2005·Oral Oncology·Federica DemarosiAndrea Sardella
Mar 18, 2010·Current Opinion in Otolaryngology & Head and Neck Surgery·Patrick J Bradley, Paula T Bradley
May 1, 2010·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Rafael E Flores-ObandoCamille C Ragin

❮ Previous
Next ❯

Citations

Jun 14, 2016·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Thomas SchlieveEric R Carlson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.